The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation and amortization expense | 124,938 | 113,209 |
| Change in value of warrant liabilities | 0 | -1,424,603 |
| Commitment shares issued for equity line of credit | 0 | 568,235 |
| Common shares issuance for services | 239,253 | 356,588 |
| Stock-based compensation | 814,932 | 1,846,465 |
| Prepaid expenses | -348,750 | -348,750 |
| Employee advances | -41,852 | 0 |
| Accounts payable | 671,563 | 1,040,656 |
| Accrued expenses | 15,140 | -140,700 |
| Accrued payroll and payroll taxes | 614 | -97,257 |
| Net loss | -6,879,530 | -8,413,481 |
| Amortization of debt discounts issuance and warrants | 0 | 0 |
| Accrued interest on convertible notes | 0 | 0 |
| Net cash used in operating activities | -4,706,192 | -5,802,138 |
| Patent license acquisition | 0 | 466,423 |
| Deferred offering costs | - | 0 |
| Net cash used in investing activities | 0 | -466,423 |
| Sale of preferred stock and related warrants | 0 | 1,053,582 |
| Common stock issuance for warrant exercise | 3,780,805 | 2,483,465 |
| Short-term borrowings | 0 | 0 |
| Short-term loan repayments | 0 | - |
| Initial public offering (net of fees) | 0 | - |
| Net proceeds from conversion of debt a, b, c, d, e & f | 0 | 0 |
| Net cash provided by financing activities | 3,780,805 | 3,537,047 |
| Net change in cash | -925,387 | -2,731,514 |
| Cash and cash equivalents at beginning of period | 5,533,527 | - |
| Cash and cash equivalents at end of period | 1,876,626 | - |
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)